ProCE Banner Activity

ENGOT-EN6-NSGO/GOG3031/RUBY: Outcomes by BICR With Addition of Dostarlimab to Carboplatin/Paclitaxel for Advanced or Recurrent Endometrial Cancer

Capsule Summary
Conference Coverage
Slideset

Efficacy analysis by independent central review from phase III RUBY trial confirms the primary report of PFS benefit with addition of dostarlimab to chemotherapy in advanced/recurrent endometrial cancer.

Released: June 09, 2023

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, GSK, and Merck Sharp & Dohme Corp.

AstraZeneca

GSK

Merck Sharp & Dohme Corp.